Actively Recruiting
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Led by Hunan Province Tumor Hospital · Updated on 2025-02-19
210
Participants Needed
1
Research Sites
170 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
CONDITIONS
Official Title
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand the trial and provide signed informed consent
- Age 18 years or older
- Confirmed advanced non-small cell lung cancer by biopsy or cytology with local progression or metastasis
- Negative for EGFR, ALK, and ROS1 mutations
- ECOG performance status of 0 or 1
- Expected survival of at least 12 weeks
- Adequate bone marrow and organ function
- Measurable tumor lesions according to RECIST 1.1
- Stable brain metastases allowed
You will not qualify if you...
- Prior systemic therapy for advanced or metastatic disease
- Treatment with chemotherapy or targeted antibodies within 4 weeks before study drug
- Radiation therapy within 14 days before study drug or unresolved radiation toxicity
- Spinal cord compression or meningeal metastasis
- Other cancers within 2 years
- Severe side effects from prior treatments above grade 1 (except hair loss)
- Stroke or brain hemorrhage within 6 months
- Severe or uncontrolled systemic diseases including uncontrolled hypertension or active bleeding
- Active infections such as hepatitis B, hepatitis C, HIV, or COVID-19
- Heart diseases or abnormalities
- Past or active interstitial lung disease or immune-related pneumonia
- Severe nausea, vomiting, swallowing difficulties, or poor drug absorption
- Live vaccines within 2 weeks before starting study drug
- Pregnant or breastfeeding women
- Allergy to study drugs or ingredients
- Any other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang C Zhang, MD
CONTACT
Y
Yongchang Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here